Successful closing: Syntegon and Telstar officially join forces

  • Strengthening strategic growth with a seamless technology and service portfolio
  • Significantly expanded pharmaceutical liquid filling offering
  • Very positive customer feedback and first inquiries for joint projects

Waiblingen (Germany), Terrassa (Spain). Following regulatory approval, Syntegon and Azbil Corporation have officially closed the acquisition of Telstar by Syntegon. The Telstar workforce will now join the Syntegon team in the Pharma Liquid Business Unit. With the joint offering of fill-finish equipment, isolator systems, freeze-dryers, loading and unloading systems as well as further upstream and downstream equipment, customers now have access to a seamless technology and service portfolio for the production of antibiotics, vaccines, or biologics.

Strengthening strategic growth

“Syntegon is world market leader in liquid vial filling and isolator systems. Together with Telstar, we will further enhance our portfolio of innovative technologies and sustainable solutions, strengthen our strategic growth, and expand our global reach,” says Torsten Türling, CEO of the Syntegon Group. “We received highly positive customer feedback and several inquiries for our joint offering following the acquisition announcement in June. This clearly shows that we are on the right track to becoming the go-to partner for seamless solutions from a single source.”

Leveraging joint expertise

“We are very much looking forward to leveraging our joint expertise for the benefits of our existing and new customers,” says Jordi Puig, Managing Director of Telstar. “By using the synergies of a strong team, we can offer truly seamless line solutions and streamlined processes with one face to the customer. This way, we will support them even better in achieving long-term stability of their pharmaceuticals and fast time to market.”

Telstar, headquartered in Terrassa (Barcelona), Spain, has four production plants, six technology centers and ten consultancy and engineering services centers, and commercial offices all over the world. By combining these capabilities with Syntegon’s global reach, both companies are now in an even better position to offer both pharmaceutical manufacturers and Contract Manufacturing Organizations (CMOs) complete line solutions. Moreover, the joint service network will be expanded significantly, adding geographical coverage, proximity, and application expertise.

Author: Torsten Türling and Jordi Puig

Author Img

Torsten Türling, CEO of the Syntegon Group, and Jordi Puig, Managing Director of Telstar, celebrate an important strategic milestone: Syntegon and Telstar have officially joined forces to offer customers even more seamless solutions and services from a single source.

Company: Syntegon Technology GmbH


Syntegon is pharmaceutical and food companies’ strategic partner for processing and packaging technology. Its 6,300-strong workforce delivers seamless processes, innovative technologies, and sustainable solutions to both industries. Syntegon’s integrated lines enable pharmaceutical companies to produce, process, fill, inspect, and package liquid and solid medicines, safely and in high quality. Food companies, in turn, count on Syntegon's flexible, reliable systems to produce and package confectionery as well as dry and frozen comestibles.

Headquartered in the Stuttgart region, Germany, Syntegon can look back on more than 160 years of experience. In 2023, the company posted annual sales of 1.5 billion euros. With a global presence of more than 35 locations in almost 20 countries and a comprehensive service portfolio, Syntegon provides a platform for seamless processes for its customers. The company’s 1,400 employees in research and development work on leading technologies every day – 2,100 patents and patent applications are proof of the processing and packaging expert innovative strength. By providing sustainable solutions, Syntegon enables the industry to switch to alternative packaging and resource-conserving production processes.

Send Enquiry for this story

By submitting this form you are giving a consent to Worldpharmatoday.com to store your submitted information.
See our Privacy Policy to learn more about how we use data.